Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Analyst Ratings
Strong Buy
23 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALNY Stock 12 Month Forecast
Average Price Target
$452.54
▼(-2.87% Downside)
| Highest Price Target$583.00 | Average Price Target$452.54 | Lowest Price Target$290.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Evercore ISI
$280→$515.05
Buy
10.55%
Upside
Reiterated
09/11/25
BMO Capital
$450→$470
Buy
0.88%
Upside
Reiterated
09/05/25
TD Cowen
$482
Buy
3.46%
Upside
Reiterated
09/02/25
H.C. Wainwright
$570
Buy
22.35%
Upside
Reiterated
09/02/25
Citi
$527→$583
Buy
25.14%
Upside
Reiterated
09/02/25
Truist Financial
―
Buy
―
Reiterated
09/02/25
Morgan Stanley
$405
Hold
-13.07%
Downside
Reiterated
09/02/25
UBS
$550
Buy
18.05%
Upside
Reiterated
09/02/25
Leerink Partners
$343→$347
Hold
-25.52%
Downside
Reiterated
09/02/25
Piper Sandler
$449
Buy
-3.63%
Downside
Reiterated
09/02/25
William Blair
―
Buy
―
Reiterated
09/01/25
Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic PartnershipsWe discuss the KARDIA-3 data further in the full note, but we expect investor questions to arise from the clinical meaningfulness of the blood pressure improvements at both 3 and 6 months, given that regulators and KOLs see a 5 mmHg benefit as the minimally important difference. We also expect investors to raise questions about thefact the KARDIA-3 study missed the primary endpoint; however, we acknowledge the unique statistical analysis plan here, which negatively impacted the 300 mg dose on the primary endpoint (p=0.04). More importantly to us, 40% of patients dosed in KARDIA-3 did not actually have systolic blood pressure >140 mmHg at baseline reading (25% had <135 mmHg) and this may have diluted the treatment effect since a substantial number of participants were not stage 2 hypertensive.
J.P. Morgan
―
Buy
―
Reiterated
08/31/25
Bernstein
$471
Buy
1.10%
Upside
Reiterated
08/22/25
We rate the following companies Outperform: REGN, ALNY, BMRN, RNA, BEAM, BHVN, and NTLA.
Stifel Nicolaus
$441
Buy
-5.34%
Downside
Reiterated
08/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
$280→$515.05
Buy
10.55%
Upside
Reiterated
09/11/25
BMO Capital
$450→$470
Buy
0.88%
Upside
Reiterated
09/05/25
TD Cowen
$482
Buy
3.46%
Upside
Reiterated
09/02/25
H.C. Wainwright
$570
Buy
22.35%
Upside
Reiterated
09/02/25
Citi
$527→$583
Buy
25.14%
Upside
Reiterated
09/02/25
Truist Financial
―
Buy
―
Reiterated
09/02/25
Morgan Stanley
$405
Hold
-13.07%
Downside
Reiterated
09/02/25
UBS
$550
Buy
18.05%
Upside
Reiterated
09/02/25
Leerink Partners
$343→$347
Hold
-25.52%
Downside
Reiterated
09/02/25
Piper Sandler
$449
Buy
-3.63%
Downside
Reiterated
09/02/25
William Blair
―
Buy
―
Reiterated
09/01/25
Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic PartnershipsWe discuss the KARDIA-3 data further in the full note, but we expect investor questions to arise from the clinical meaningfulness of the blood pressure improvements at both 3 and 6 months, given that regulators and KOLs see a 5 mmHg benefit as the minimally important difference. We also expect investors to raise questions about thefact the KARDIA-3 study missed the primary endpoint; however, we acknowledge the unique statistical analysis plan here, which negatively impacted the 300 mg dose on the primary endpoint (p=0.04). More importantly to us, 40% of patients dosed in KARDIA-3 did not actually have systolic blood pressure >140 mmHg at baseline reading (25% had <135 mmHg) and this may have diluted the treatment effect since a substantial number of participants were not stage 2 hypertensive.
J.P. Morgan
―
Buy
―
Reiterated
08/31/25
Bernstein
$471
Buy
1.10%
Upside
Reiterated
08/22/25
We rate the following companies Outperform: REGN, ALNY, BMRN, RNA, BEAM, BHVN, and NTLA.
Stifel Nicolaus
$441
Buy
-5.34%
Downside
Reiterated
08/14/25
Best Analysts Covering Alnylam Pharma
1 Month
xxx
Success Rate
16/27 ratings generated profit
Average Return
+1.16%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +1.16% per trade.
3 Months
xxx
Success Rate
22/31 ratings generated profit
Average Return
+12.36%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.97% of your transactions generating a profit, with an average return of +12.36% per trade.
1 Year
Success Rate
21/23 ratings generated profit
Average Return
+44.61%
reiterated a buy rating 10 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 91.30% of your transactions generating a profit, with an average return of +44.61% per trade.
2 Years
xxx
Success Rate
23/23 ratings generated profit
Average Return
+105.09%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +105.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALNY Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
6
5
3
1
0
Buy
51
35
41
41
44
Hold
19
15
13
15
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
76
55
57
57
58
Each month's total comprises the sum of three months' worth of ratings.
ALNY Financial Forecast
ALNY Stock Forecast FAQ
What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 452.54.
What is ALNY’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ALNY, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALNY a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 23 buy ratings, 5 hold ratings and 0 sell ratings.
What is Alnylam Pharmaceuticals’s price target?
The average price target for Alnylam Pharmaceuticals is 452.54. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $583.00 ,the lowest forecast is $290.00. The average price target represents -2.87% Decrease from the current price of $465.89.
The highest analyst price target is $583.00 ,the lowest forecast is $290.00. The average price target represents -2.87% Decrease from the current price of $465.89.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 28 Wall Streets Analysts.
How can I buy shares of ALNY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.